search
Back to results

Dermal Cryotherapy for Treatment of Pigmented Lesions

Primary Purpose

Pigmented Skin Lesion

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Dermal Cooling System
Sponsored by
R2 Dermatology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pigmented Skin Lesion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects > 18 years of age.
  2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma, freckles, café au lait, nevi, or hyperpigmentation), in an area suitable for treatment
  3. Subject is willing to have up to 40 treatment sites and/or an area up to 8 square inches treated depending on the size and nature of the lesions identified.
  4. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes.
  5. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated areas for the duration of the study, including the follow-up period, if requested.
  6. Subject has read and signed a written informed consent form.

Exclusion Criteria:

  1. Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery)
  2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period
  3. Scars or tattoos in the location of the treatment sites
  4. History of vitiligo, eczema, or psoriasis in the area of treatment
  5. History of melanoma
  6. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.
  7. History of abnormal wound healing or abnormal scarring
  8. Inability or unwillingness to comply with the study requirements.
  9. Current enrollment in a clinical study of any other unapproved investigational drug or device.
  10. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Sites / Locations

  • Diablo Clinical Research
  • Arbutus Laser Centre

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment with cryotherapy device

Arm Description

To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.

Outcomes

Primary Outcome Measures

Reduction of pigmentation in treated lesions
Changes in pigmentation graded using a 4-point standardized scale

Secondary Outcome Measures

Evaluation of device- or procedure-related adverse events
Side effects, discomfort assessments both during treatment and follow-up

Full Information

First Posted
July 26, 2016
Last Updated
March 25, 2021
Sponsor
R2 Dermatology
search

1. Study Identification

Unique Protocol Identification Number
NCT02848742
Brief Title
Dermal Cryotherapy for Treatment of Pigmented Lesions
Official Title
Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
June 2016 (undefined)
Primary Completion Date
March 2020 (Actual)
Study Completion Date
March 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
R2 Dermatology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign pigmented lesions.
Detailed Description
This study is a prospective, non-randomized, multi-center study of the Dermal Cooling System to verify that the device causes a reduction in pigmentation in benign pigmented lesions, and to determine at what parameters the device is most effective.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pigmented Skin Lesion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
377 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment with cryotherapy device
Arm Type
Experimental
Arm Description
To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
Intervention Type
Device
Intervention Name(s)
Dermal Cooling System
Intervention Description
Dermal cryotherapy
Primary Outcome Measure Information:
Title
Reduction of pigmentation in treated lesions
Description
Changes in pigmentation graded using a 4-point standardized scale
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Evaluation of device- or procedure-related adverse events
Description
Side effects, discomfort assessments both during treatment and follow-up
Time Frame
0 to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects > 18 years of age. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma, freckles, café au lait, nevi, or hyperpigmentation), in an area suitable for treatment Subject is willing to have up to 40 treatment sites and/or an area up to 8 square inches treated depending on the size and nature of the lesions identified. Subject is willing to have digital photographs taken of the treatment area and agrees to use of photographs for presentation, educational, or marketing purposes. Subject is willing to cover treated area or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated areas for the duration of the study, including the follow-up period, if requested. Subject has read and signed a written informed consent form. Exclusion Criteria: Physician prescribed medical or surgical treatment, or use of over-the-counter products to alter skin color, in the area of intended treatment in the previous 6 months (e.g., hydroquinone, corticosteroids, laser surgery) Artificial tanning in the area of intended treatment within 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period Scars or tattoos in the location of the treatment sites History of vitiligo, eczema, or psoriasis in the area of treatment History of melanoma Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease. History of abnormal wound healing or abnormal scarring Inability or unwillingness to comply with the study requirements. Current enrollment in a clinical study of any other unapproved investigational drug or device. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristine Tatsutani, PhD
Organizational Affiliation
R2 Dermatology, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Diablo Clinical Research
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Arbutus Laser Centre
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6J 1Z6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dermal Cryotherapy for Treatment of Pigmented Lesions

We'll reach out to this number within 24 hrs